Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly to Pause Enrollment in Most Drug Trials

By Prosper Junior Bakiny - Mar 23, 2020 at 4:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clinical trials require contract between patients and researchers -- just the sort of thing we're being advised to limit amid the COVID-19 pandemic.

Pharmaceutical giant Eli Lilly (LLY 4.12%) has been doing its part in the battle against COVID-19. It teamed up with the Indiana State Department of Health to make more testing for the disease available to people in its home state, and plans to start offering drive-thru testing for COVID-19 to active healthcare workers there. But in light of the threat the novel coronavirus poses, and the need for people to reduce human contact to slow its spread, the company is now making a significant change to its clinical trial activities.

While Eli Lilly will continue conducting clinical trials with patients who are already enrolled in them, it will no longer enroll new patients for its ongoing studies, and will also postpone the start of new ones. 

Doctor in a lab wearing goggles and holding test tube filled with a red liquid.

Image Source: Getty Images.


Clinical trials typically involve close interactions between patients and researchers. Since COVID-19 spreads primarily person to person, such contacts between patients and physicians put everyone involved at risk of spreading the disease. In light of that, the U.S. Food and Drug Administration recently issued new guidance to drugmakers for conducting clinical trials. 

Other companies have decided to halt some clinical trials because of the pandemic. For instance, clinical-stage biotech company Provention Bio (PRVB 4.94%) chose to pause its phase 3 PROTECT Study, which was investigating the efficacy of PRV-031 as a treatment for newly diagnosed type 1 diabetes. Other biotech companies could announce similar measures in the weeks to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$325.62 (4.12%) $12.90
Provention Bio, Inc. Stock Quote
Provention Bio, Inc.
PRVB
$4.25 (4.94%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.